Article Details
Retrieved on: 2024-05-16 14:42:15
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Roche’s positive Phase Ib trial results for CT-388, a GLP-1 receptor and GIP receptor agonist for obesity and diabetes, situated within the broader biotech and peptide therapeutic industry. Competitors like Novo Nordisk and Eli Lilly are prominently mentioned.
Article found on: www.clinicaltrialsarena.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here